Drug Trial Radar · NCT07290777
VEL-101 to Prevent Rejection After Kidney Transplantation
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Aug 18, 2026
Primary completion
Oct 2028
Study completion Oct 2028
Sponsor
- Lead sponsor
- Asahi Kasei Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of VEL-101 compared with tacrolimus in patients undergoing kidney transplantation.
Conditions
- Transplantation, Kidney
Interventions
Tacrolimus (TAC)Drug
Tacrolimus Immediate Release in addition to SOC
VEL-101Drug
VEL-101 in addition to SOC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of serious adverse events (SAEs)Time frame: Month 12
- Incidence of treatment emergent adverse events (TEAEs)Time frame: Month 12
- PK Parameter CmaxTime frame: Day 1, Month 3
- PK Parameter CminTime frame: Day 1, Month 3
- PK Parameter TmaxTime frame: Day 1, Month 3
- AUC from 0-8 hoursTime frame: Day 1, Month 3
- AUC from 0 to 48 hoursTime frame: Day 2
- VEL-101 Accumulation RatioTime frame: Month 3
- VEL-101 Pre-Dose Serum ConcentrationTime frame: Day 1, Day 14, Months 1, 2, 3, 6, 9, 12, Periprocedural (kidney biospy)
- Effect of Anti-Drug Antibody (ADA) Development on VEL-101 Serum ConcentrationTime frame: Months 1, 2, 3, 6, 9, 12, Periprocedural (kidney biopsy)
- Effect of Neutralizing Antibody (NAb) Development on VEL-101 Serum ConcentrationTime frame: Day 1, Months 1, 2, 3, 6, 9, 12 and Periprocedural (kidney biopsy)
- VEL-101 CD28 Receptor Occupancy Concentration (%)Time frame: Days 1, 2, 3, 4, 5, 7, 14, 42, 70, 82, 91, 98 and Months 1, 2, 3, 6, 9, 12 and Periprocedural (kidney biopsy)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
USA Site #1087
Dallas, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.